欧洲可通过疫苗预防的癌症死亡率的负担和间接成本。

IF 2.9 4区 医学 Q2 HEALTH CARE SCIENCES & SERVICES
Journal of Medical Economics Pub Date : 2024-04-01 Epub Date: 2024-07-15 DOI:10.1080/13696998.2024.2374684
Goran Bencina, Ugne Sabale, Edith Morais, Olga Ovcinnikova, Edward Oliver, Hayley Shoel, Anne Meiwald, Robert Hughes, Georgie Weston, Karin Sundström
{"title":"欧洲可通过疫苗预防的癌症死亡率的负担和间接成本。","authors":"Goran Bencina, Ugne Sabale, Edith Morais, Olga Ovcinnikova, Edward Oliver, Hayley Shoel, Anne Meiwald, Robert Hughes, Georgie Weston, Karin Sundström","doi":"10.1080/13696998.2024.2374684","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The economic and mortality burden of cancer is high worldwide. In Europe, cancer was responsible for 1.3 million deaths in 2020 and incurred an estimated cost of €50 billion from premature mortality. Human papillomavirus (HPV) and hepatitis B virus (HBV) are among the leading causes of infection-related cancers despite the availability of effective vaccines against these infections. This analysis estimated the mortality and productivity loss of HBV- and HPV-associated cancers that could be preventable through vaccination across European regions.</p><p><strong>Materials and methods: </strong>Institute for Health Metrics Evaluation (IHME) data were used to estimate mortality, years of life lost (YLL), and the value of years of life lost (VYLL) from five HBV- and HPV-related cancers (oral cavity, oropharynx, larynx, cervical, and liver cancers) across 40 European countries in 2019. Preventable deaths and YLL were estimated based on fractions attributable to infections. Data from the World Bank on GDP per capita were used to estimate the VYLL. The robustness of these results was explored with sensitivity and scenario analyses.</p><p><strong>Results: </strong>In 2019, 31,906 cancer deaths resulted in an economic burden of €18,521,614,725 due to productivity losses across Europe. HPV-related cervical cancer had the highest mortality (19,473 deaths) and economic burden (€10,706,253,185). HBV-related liver cancer and HPV-related larynx, oral cavity, and oropharynx cancers also had a substantial burden, particularly in males. Eastern Europe had the highest YLL (308,179; 39%) and Western Europe was responsible for the greatest VYLL (€8,281,306,504; 45%), although the highest VYLL per death was in Northern Europe (€923,638). HPV-related oropharynx cancer had the highest VYLL per death (€656,607).</p><p><strong>Conclusion: </strong>HPV- and HBV-related cancer deaths are associated with substantial mortality and productivity losses in Europe, which could be reduced by the continued prioritization and implementation of prophylactic public health measures including systematic awareness, vaccination, and screening efforts.</p>","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":"27 sup2","pages":"30-40"},"PeriodicalIF":2.9000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Burden and indirect cost of vaccine-preventable cancer mortality in Europe.\",\"authors\":\"Goran Bencina, Ugne Sabale, Edith Morais, Olga Ovcinnikova, Edward Oliver, Hayley Shoel, Anne Meiwald, Robert Hughes, Georgie Weston, Karin Sundström\",\"doi\":\"10.1080/13696998.2024.2374684\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The economic and mortality burden of cancer is high worldwide. In Europe, cancer was responsible for 1.3 million deaths in 2020 and incurred an estimated cost of €50 billion from premature mortality. Human papillomavirus (HPV) and hepatitis B virus (HBV) are among the leading causes of infection-related cancers despite the availability of effective vaccines against these infections. This analysis estimated the mortality and productivity loss of HBV- and HPV-associated cancers that could be preventable through vaccination across European regions.</p><p><strong>Materials and methods: </strong>Institute for Health Metrics Evaluation (IHME) data were used to estimate mortality, years of life lost (YLL), and the value of years of life lost (VYLL) from five HBV- and HPV-related cancers (oral cavity, oropharynx, larynx, cervical, and liver cancers) across 40 European countries in 2019. Preventable deaths and YLL were estimated based on fractions attributable to infections. Data from the World Bank on GDP per capita were used to estimate the VYLL. The robustness of these results was explored with sensitivity and scenario analyses.</p><p><strong>Results: </strong>In 2019, 31,906 cancer deaths resulted in an economic burden of €18,521,614,725 due to productivity losses across Europe. HPV-related cervical cancer had the highest mortality (19,473 deaths) and economic burden (€10,706,253,185). HBV-related liver cancer and HPV-related larynx, oral cavity, and oropharynx cancers also had a substantial burden, particularly in males. Eastern Europe had the highest YLL (308,179; 39%) and Western Europe was responsible for the greatest VYLL (€8,281,306,504; 45%), although the highest VYLL per death was in Northern Europe (€923,638). HPV-related oropharynx cancer had the highest VYLL per death (€656,607).</p><p><strong>Conclusion: </strong>HPV- and HBV-related cancer deaths are associated with substantial mortality and productivity losses in Europe, which could be reduced by the continued prioritization and implementation of prophylactic public health measures including systematic awareness, vaccination, and screening efforts.</p>\",\"PeriodicalId\":16229,\"journal\":{\"name\":\"Journal of Medical Economics\",\"volume\":\"27 sup2\",\"pages\":\"30-40\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2024-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Medical Economics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/13696998.2024.2374684\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/7/15 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Economics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13696998.2024.2374684","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/15 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

摘要

背景:癌症给全世界造成了沉重的经济和死亡负担。在欧洲,2020 年有 130 万人死于癌症,过早死亡造成的损失估计达 500 亿欧元。人类乳头瘤病毒(HPV)和乙型肝炎病毒(HBV)是导致感染相关癌症的主要原因之一,尽管目前已有针对这些感染的有效疫苗。这项分析估计了欧洲各地区可通过接种疫苗预防的 HBV 和 HPV 相关癌症的死亡率和生产力损失:使用卫生计量评估研究所(IHME)的数据估算了2019年欧洲40个国家中五种HBV和HPV相关癌症(口腔癌、口咽癌、喉癌、宫颈癌和肝癌)的死亡率、生命损失年数(YLL)和生命损失年数价值(VYLL)。可预防的死亡人数和 YLL 是根据可归因于感染的比例估算的。世界银行的人均 GDP 数据用于估算 VYLL。通过敏感性分析和情景分析探讨了这些结果的稳健性:2019 年,31,906 例癌症死亡导致欧洲生产力损失,造成 18,521,614,725 欧元的经济负担。与 HPV 相关的宫颈癌死亡率最高(19473 例死亡),造成的经济负担也最高(10706253185 欧元)。与 HBV 相关的肝癌和与 HPV 相关的喉癌、口腔癌和口咽癌也造成了巨大的负担,尤其是对男性而言。东欧的年死亡率最高(308 179;39%),西欧的年死亡率最高(8 281 306 504 欧元;45%),但北欧的年死亡率最高(923 638 欧元)。与 HPV 相关的口咽癌每例死亡的 VYLL 最高(656,607 欧元):结论:在欧洲,与 HPV 和 HBV 相关的癌症死亡与大量的死亡率和生产力损失有关,而通过继续优先考虑和实施预防性公共卫生措施,包括系统的宣传、疫苗接种和筛查工作,可以减少这些损失。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Burden and indirect cost of vaccine-preventable cancer mortality in Europe.

Background: The economic and mortality burden of cancer is high worldwide. In Europe, cancer was responsible for 1.3 million deaths in 2020 and incurred an estimated cost of €50 billion from premature mortality. Human papillomavirus (HPV) and hepatitis B virus (HBV) are among the leading causes of infection-related cancers despite the availability of effective vaccines against these infections. This analysis estimated the mortality and productivity loss of HBV- and HPV-associated cancers that could be preventable through vaccination across European regions.

Materials and methods: Institute for Health Metrics Evaluation (IHME) data were used to estimate mortality, years of life lost (YLL), and the value of years of life lost (VYLL) from five HBV- and HPV-related cancers (oral cavity, oropharynx, larynx, cervical, and liver cancers) across 40 European countries in 2019. Preventable deaths and YLL were estimated based on fractions attributable to infections. Data from the World Bank on GDP per capita were used to estimate the VYLL. The robustness of these results was explored with sensitivity and scenario analyses.

Results: In 2019, 31,906 cancer deaths resulted in an economic burden of €18,521,614,725 due to productivity losses across Europe. HPV-related cervical cancer had the highest mortality (19,473 deaths) and economic burden (€10,706,253,185). HBV-related liver cancer and HPV-related larynx, oral cavity, and oropharynx cancers also had a substantial burden, particularly in males. Eastern Europe had the highest YLL (308,179; 39%) and Western Europe was responsible for the greatest VYLL (€8,281,306,504; 45%), although the highest VYLL per death was in Northern Europe (€923,638). HPV-related oropharynx cancer had the highest VYLL per death (€656,607).

Conclusion: HPV- and HBV-related cancer deaths are associated with substantial mortality and productivity losses in Europe, which could be reduced by the continued prioritization and implementation of prophylactic public health measures including systematic awareness, vaccination, and screening efforts.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Medical Economics
Journal of Medical Economics HEALTH CARE SCIENCES & SERVICES-MEDICINE, GENERAL & INTERNAL
CiteScore
4.50
自引率
4.20%
发文量
122
期刊介绍: Journal of Medical Economics'' mission is to provide ethical, unbiased and rapid publication of quality content that is validated by rigorous peer review. The aim of Journal of Medical Economics is to serve the information needs of the pharmacoeconomics and healthcare research community, to help translate research advances into patient care and be a leader in transparency/disclosure by facilitating a collaborative and honest approach to publication. Journal of Medical Economics publishes high-quality economic assessments of novel therapeutic and device interventions for an international audience
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信